Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Andromed, Inc.
Medical device company reports quarterly loss of $0.03 per share
August 10th, 2005
Andromed, Inc., (AD) reported on its business and financial results for the quarter ended May 31, 2005. During the second quarter, Andromed achieved an important milestone by successfully completing its clinical trial on Androflo and by filing a U.S. Food & Drug Administration marketing approval application for this product. Moreover, Andromed has continued to focus on raising the company 's technological and strategic value in order to conclude a transaction leading to a merger or the complete or partial sale of the company by the end of 2005. Its efforts are centred on a value enhancement plan featuring the following: ...
Source: Biotech Week (2005-08-10)
|
